Evidence map›Paper›PMID 31256317›Full record

SynthesisHeart failure reviews2020

A comparison of anticoagulation, antiplatelet, and placebo treatment for patients with heart failure reduced ejection fraction in sinus rhythm: a systematic review and meta-analysis.

Elisabeth M Sulaica, Tracy E Macaulay, Rachel R Helbing, Mohamed Abo-Aly, Ahmed Abdel-Latif, Matthew A Wanat

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Heart failure reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Elisabeth M SulaicaDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, 4849 Calhoun Road - Health 2, Room 3044, Houston, TX, 77204-5039, USA. emsulaic@central.uh.edu.ORCID 0000-0002-5655-5318
Tracy E MacaulayDepartment of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, 789 S. Limestone Street, TODD 232, Lexington, KY, 40536, USA.
Rachel R HelbingUniversity Libraries, University of Houston, 4849 Calhoun Rd Health 2, Houston, TX, 77204-5039, USA.
Mohamed Abo-AlyGill Heart & Vascular Institute, University of Kentucky, 741 S. Limestone, BBSRB B343, Lexington, KY, 40536-0509, USA.
Ahmed Abdel-LatifGill Heart & Vascular Institute, University of Kentucky, 741 S. Limestone, BBSRB B343, Lexington, KY, 40536-0509, USA.
Matthew A WanatDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, 4849 Calhoun Road - Health 2, Room 3044, Houston, TX, 77204-5039, USA.
University of Houston · USUniversity of Kentucky · US

Funding

The role of IKKß in linking obesity to adipose tissue inflammation and adipogeneP20GM103527 · NIGMS · UNIVERSITY OF KENTUCKY · PI MORRIS, ANDREW J · 2012 to 2017
$13.7M
NIGMS NIH HHS P20 GM103527
6 · The paper itself

Abstract

Previous meta-analyses have not recommended routine warfarin use in heart failure (HF) patients but included limited data on contemporary anticoagulants and practices. We conducted an updated meta-analysis in light of newer literature evaluating rivaroxaban in this patient population. The aim of this meta-analysis was to assess if anticoagulation is associated with a decrease in all-cause mortality, myocardial infarction (MI), stroke, and hospitalization for HF exacerbation without an increased risk of major bleeding. A systematic search was conducted for randomized controlled trials to evaluate the use of antithrombotic therapy in patients with HF in sinus rhythm. Outcomes evaluated included all-cause mortality (ACM), non-fatal stroke, MI, hospitalization for HF exacerbation, and major bleeding. Five trials met criteria with a total of 9390 patients included. Four of the five trials evaluated warfarin use and one trial evaluated rivaroxaban. When anticoagulation was compared to control (antiplatelet and placebo groups), a significant reduction in ischemic stroke was found (OR 0.57; 95% CI, 0.42 to 0.78; P = 0.0005, I

Indexed as

AnticoagulantsHeart FailureHeart RateHumansPlatelet Aggregation InhibitorsRandomized Controlled Trials as TopicStroke VolumeAnticoagulantsPlatelet Aggregation InhibitorsAnticoagulationHeart failureRivaroxabanSinus rhythmWarfarin

Identifiers

PMID31256317
OpenAlexW2954664694

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.